Key result
A CAN Risk Score of 4 or higher demonstrated good diagnostic accuracy for confirmed cardiovascular autonomic neuropathy in type 1 diabetes, yielding an AUC of 0.802 and a negative predictive value of 96.4%.
Why the study?
A previously developed CAN Risk Score in type 1 diabetes required validation for cardiovascular autonomic neuropathy in an independent external population.
Does the CAN Risk Score accurately identify the presence of confirmed cardiovascular autonomic neuropathy in patients with type 1 diabetes?
Cross-Sectional (n=47)
No
Does the CAN Risk Score accurately identify the presence of confirmed cardiovascular autonomic neuropathy in patients with type 1 diabetes?
Effect estimate: AUC 0.802
p-value: p=0.0129
The CAN Risk Score is a simple, externally validated tool using routine clinical data that can accurately identify type 1 diabetes patients at low risk for cardiovascular autonomic neuropathy, thereby reducing the need for universal screening with specialized reflex tests.
External validation supports CAN Risk Score diagnostic utility in T1D; leaves open whether it improves outcomes or warrants routine use.
AIMS: To validate in an independent external population a CAN Risk Score previously developed in type 1 diabetes (T1D) and validated for cardiovascular autonomic neuropathy (CAN) with a good diagnostic accuracy. METHODS: Forty-seven participants with T1D (age 47.7 ± 13.2 years, duration of diabetes 30.0 (19.0-40.5) years, 24 males) underwent 4 cardiovascular reflex tests (CARTs) to diagnose early and confirmed CAN (according to 1 or 2 abnormal results). CAN Risk Score was calculated from resting heart rate, HbA1c, retinopathy and/or nephropathy, cardiovascular disease, HDL cholesterol, systolic blood pressure and smoking (range 0-10). RESULTS: Eleven participants (23.4 %) had CAN. The CAN Risk Score was higher in subjects with overall CAN (early and confirmed) (P = 0.0498) and with confirmed CAN (P = 0.0142) compared to those without, and correlated with CARTs severity (rho = 0.32, P = 0.026), Expiration/Inspiration ratio (r = -0.33, P = 0.0258) and Valsalva ratio (r = -0.47, P = 0.0015). A CAN Risk Score ≥ 4 was found in 19 participants and was associated with the presence of confirmed CAN (P = 0.0129). The CAN Risk Score showed an area under the ROC curve (AUC) of 0.802 ± 0.080 for confirmed CAN, and at the cut-off of 4, sensitivity, specificity and negative predictive values of 85.71 %, 67.50 % and 96.43 %. CONCLUSIONS: This study confirmed the diagnostic value of the CAN Risk Score and supports its inclusion in a diagnostic algorithm to identify candidates for CARTs, thereby reducing universal screening. Using routinely available clinical data as categorical variables, the score is easy to calculate and implement in clinical settings.
No takes yet. Share an insight, caveat, or question.
D’Ippolito et al. (2025) conducted a cross-sectional in Type 1 diabetes and cardiovascular autonomic neuropathy (n=47). CAN Risk Score ≥ 4 vs. CAN Risk Score < 4 was evaluated on Diagnostic accuracy for confirmed cardiovascular autonomic neuropathy (AUC) (AUC 0.802, p=0.0129). A CAN Risk Score of 4 or higher demonstrated good diagnostic accuracy for confirmed cardiovascular autonomic neuropathy in type 1 diabetes, yielding an AUC of 0.802 and a negative predictive value of 96.4%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: